A randomized, double-blind, phase 3 safety and efficacy study of ridinilazole versus vancomycin for treatment of Clostridioides difficile infection: Clinical outcomes with microbiome and metabolome correlates of response

Authors

Pablo C Okhuysen, University of Texas M.D. Anderson Cancer Center
Erik R Dubberke, Washington University School of Medicine in St. Louis
et al.

Journal

Clinical infectious diseases

Publication Date

6-14-2024

Volume

78

Issue

6

First Page

1462

Last Page

1472

Document Type

Open Access Publication

DOI

10.1093/cid/ciad792

Rights and Permissions

Pablo C Okhuysen, Mayur S Ramesh, Thomas Louie, Nino Kiknadze, Julian Torre-Cisneros, Claudia Murta de Oliveira, Christophe Van Steenkiste, Alena Stychneuskaya, Kevin W Garey, Julia Garcia-Diaz, Jianling Li, Esther Duperchy, Betty Y Chang, Juthamas Sukbuntherng, Jose G Montoya, Lori Styles, Fong Clow, Danelle James, Erik R Dubberke, Mark Wilcox, A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response, Clinical Infectious Diseases, Volume 78, Issue 6, 15 June 2024, Pages 1462–1472, https://doi.org/10.1093/cid/ciad792. © The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Recommended Citation

Okhuysen, Pablo C; Dubberke, Erik R; and et al., "A randomized, double-blind, phase 3 safety and efficacy study of ridinilazole versus vancomycin for treatment of Clostridioides difficile infection: Clinical outcomes with microbiome and metabolome correlates of response." Clinical infectious diseases. 78, 6. 1462 - 1472. (2024).
https://digitalcommons.wustl.edu/oa_4/3876

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.